{"id":"NCT00577460","sponsor":"Boehringer Ingelheim","briefTitle":"Long-term Safety Study of Open-label Pramipexole ER in Patients With Advanced PD","officialTitle":"Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Advanced Parkinson's Disease (PD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-12","primaryCompletion":"2010-06","completion":null,"firstPosted":"2007-12-20","resultsPosted":"2011-07-14","lastUpdate":"2014-05-16"},"enrollment":391,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson Disease"],"interventions":[{"type":"DRUG","name":"Pramipexole","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Pramipexole","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The general aim of this study is to obtain long-term safety and tolerability data on pramipexole extended release (ER), in daily doses from 0.375mg to 4.5mg once daily (qd), in patients who have previously completed a pramipexole double-blind study in advanced Parkinson's disease (PD) (248.525 trial).","primaryOutcome":{"measure":"Percentage of Patients With Adverse Events, Adverse Drug Reactions, Serious Adverse Events","timeFrame":"80 weeks","effectByArm":[{"arm":"Placebo","deltaMin":85.3,"sd":null},{"arm":"PPX ER","deltaMin":83.7,"sd":null},{"arm":"PPX IR","deltaMin":79.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"32 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":70,"countries":["Austria","Czechia","Hungary","India","Italy","Philippines","Poland","Russia","Slovakia","South Korea","Spain","Sweden","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":129},"commonTop":["Dyskinesia","Somnolence","Dizziness","Insomnia","Nausea"]}}